Journal
BRITISH JOURNAL OF PHARMACOLOGY
Volume 143, Issue 8, Pages 933-937Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/sj.bjp.0705973
Keywords
breast cancer; GW9662; peroxisome proliferator-activated receptor (PPAR); PPAR gamma; rosiglitazone
Categories
Funding
- Breast Cancer Now [2001:231] Funding Source: Medline
Ask authors/readers for more resources
Peroxisome proliferator-activated receptor gamma (PPARgamma), a member of the nuclear receptor superfamily, is activated by several compounds, including the thiazolidinediones. In addition to being a therapeutic target for obesity, hypolipidaemia and diabetes, perturbation of PPARgamma signalling is now believed to be a strategy for treatment of several cancers, including breast. Although differential expression of PPARgamma is observed in tumours compared to normal tissues and PPARgamma agonists have been shown to inhibit tumour cell growth and survival, the interdependence of these observations is unclear. This study demonstrated that the potent, irreversible and selective PPARgamma antagonist GW9662 prevented activation of PPARgamma and inhibited growth of human mammary tumour cell lines. Controversially, GW9662 prevented rosiglitazone-mediated PPARgamma activation, but enhanced rather than reversed rosiglitazone-induced growth inhibition. As such, these data support the existence of PPARgamma-independent pathways and question the central belief that PPARgamma ligands mediate their anticancer effects via activation of PPARgamma.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available